Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.

Claudia KesslerAlessa PardoMehmet K TurStefan GattenlöhnerRainer FischerKatharina KolbergStefan Barth

Published in: Journal of cancer research and clinical oncology (2017)

Our data demonstrate, for the first time, the specific binding, internalization, and cytotoxicity of a scFv-based fusion protein targeting PSCA. Immunohistochemical staining confirmed the specific ex vivo binding to primary PCa material.

Keyphrases

prostate cancer
cancer therapy
radical prostatectomy
electronic health record
dna binding
deep learning